Pitavastatin

Drug Profile

Pitavastatin

Alternative Names: Alipza; Itavastatin; Livalo; Livazo; Nisvastatin; NK 104; NK-104-CR; NK-104-LH; NK-104-PH; NKS 104; P 872441; Pitavastatin Calcium; Redevant; Trolise; Vezepra

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Nissan Chemical Industries
  • Developer AbbVie; Algorithm; Daiichi Sankyo Company; Eli Lilly; ESTEVE; JW Pharmaceutical; Kowa; Mitsubishi Tanabe Pharma Corporation; Nissan Chemical Industries; Recordati
  • Class Antihyperlipidaemics; Carboxylic acids; Cyclopropanes; Fluorobenzenes; Quinolines; Small molecules
  • Mechanism of Action HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Dyslipidaemias; Hypercholesterolaemia; Hyperlipidaemia
  • Registered Hyperlipoproteinaemia type IIa
  • Discontinued Alzheimer's disease

Most Recent Events

  • 19 Apr 2017 Efficacy and adverse events data from the phase IV INTREPID trial in Dyslipidaemias released by (Company)
  • 17 Jan 2017 Kowa and Nissan Chemical Industries enter into an agreement with Zydus to settle patent litigation related to generic version of pitvastatin in USA
  • 29 Jun 2016 Kowa completes a phase II extension trial for Hyperlipoproteinaemia type IIa (In adolescents, In children, In infants) in Japan (JapicCTI132146)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top